Biopharma pharmaceutical company is mulling the possibility of building fractionation plants in Latin America and Africa, co-owner of the company Kostiantyn Yefymenko has said.
“Our next project will be the construction of a blood fractionation plant on other continents. We are now considering Latin America and Africa,” he said during a discussion at the Kyiv International Economic Forum.
Yefymenko noted that currently Biopharma chooses “between Egypt and Nigeria.”
“We associate this with the political situation in both countries. Our next investment will be the expansion of the business of blood plasma fractionation and the construction of plasma centers in these countries,” he said.
Biopharma is a Ukrainian biotechnology company, the only plant in Eastern Europe that has modern technologies, and has been producing and developing medicines from donated plasma for almost 50 years.
The company is focused on providing Ukraine with medicines and supplies its products to more than 30 countries of the world on a contractual basis. In the autumn of 2019, Biopharma moved its production to a new scientific and production complex in Bila Tserkva.
The company is developing a network of its own plasma centers. Now they work in Sumy, Shostka, Konotop, Cherkasy, Dnipro and Kharkiv.
BIOPHARMA, biotechnology, LATIN AMERICA, MEDICAL COMPANIES
